IntOGen - Cancer Drivers Actionability Database

Rubio Pérez, Carlota; Tamborero Noguera, David; Schroeder, Michael Philipp, 1986-; Antolín Hernández, Albert, 1984-; Déu Pons, Jordi; Pérez Llamas, Christian, 1976-; Mestres i López, Jordi; González-Pérez, Abel; López Bigas, Núria

IntOGen - Cancer Drivers Actionability Database

License

Citation

Rubio Pérez, C, Tamborero Noguera, D, Schroeder, M, Antolín Hernández, A, Déu Pons, J, Pérez Llamas, C, Mestres i López, J, et al. . IntOGen - Cancer Drivers Actionability Database. Universitat Pompeu Fabra; 2015. handle: http://hdl.handle.net/10230/28050

This citation was generated automatically.

Abstract

This database contains data on the interactions with therapeutic agents an driver genes contained in Cancer Drivers Database (2014.12). It characterizes the interacting therapeutic agents in terms of clinical phase and cancer prescription, among other features. Additionally, it contains ancillary information on specific genomic alterations associated to drug effectiveness which are FDA approved or clinically being tested together with data on other genomic alterations known to be responsible of drug primary resistance.

Description

File contents/n-----------------/nProtein_Drug_Interactions.tsv/nInteractions of 96/475 cancer driver genes in Drivers Database with therapeutic agents/nProtein_druggability.tsv/nExclusvie druggability of 157/475 driver genes according interactions in Protein_Drug_Interactions.tsv/nDrug_details.tsv/nDescription of each drug/nDrug_FDAapproved_rules.tsv/nRules for prescription of FDA approved drugs to genomic alterations/nDrug_ClinicalTrials_rules.tsv/nRules for prescription of drugs in clinical trials to genomic alterations/nDrug_resistances_rules.tsv/nRules for not prescribing drugs to samples bearing genomic alterations of primary resistance/n/nSpecificities/n-----------------/n*In most of the files tumor types are represented through its acronyms (see Drivers Database)/n*Specific genomic dependencies/evidences/resistances are codified in the same unified code in the Columns () in the files (Drug_resistances_rules.tsv, Drug_FDAapproved_rules.tsv, Drug_ClinicalTrials_rules.tsv). /nThe coding rules are:/n- All of them are divided in mutations/CNAs/fusions. /n- For each one, different genes with alterations are semicolon (;) divided./n- Each gene differs from its alterions with colon(:) and its different alterations are comma (,) divided. /ni.e BRAF:V600E,V600K (two diferent alterations)/n- For CNAs A stants for Amplification and D for delention./ni.e. FGFR1:A/n- For mutations all of them are specified at protein level lik referenceAA+proteinposition+alteredAA./ni.e. BRAF:V600E,V600K/n except mutational requirements not based on AA change but specific consequence type, which are specified by ::CT:: after the gene./ni.e. NOTCH1::CT::missense_variant:2380-2445;CT::feature_truncation:2380-2445/n- Fusion partners are divided with dash (-)./ni.e. BCR-ABL1/n- A dot (.) represents any./ni.e. BRAF:V600. (any alteredAA)/ni.e. BRAF:. (any PAM mutation)

Referenced by

http://dx.doi.org/10.1016/j.ccell.2015.02.007

Related Publication/Data

Més informació: IntOGen (web)
Rubio-Perez C, Tamborero D, Schroeder MP, Aantolín AA, Deu-Pons J, Perez-Llamas C, Mestres J, Gonzalez-Perez A, Lopez-Bigas N. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell. 2015; 27(3): 382-96. DOI: 10.1016/j.ccell.2015.02.007

Full item page